Evidence map›Paper›PMID 35037899›Full record

ReviewAging2022

Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.

Xunrui Chen, Wenhui Zhang, Wenyan Yang, Min Zhou, Feng Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8Journal for immunotherapy of cancer · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xunrui ChenDepartment of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China.
Wenhui ZhangShanghai Institute of Precision Medicine, Shanghai 200125, China.
Wenyan YangMedical Center, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201900, China.
Min ZhouDepartment of Respirtory Medicine, Jinshan Branch of the Sixth People's Hospital of Shanghai, Shanghai 201599, P.R. China.
Feng LiuDepartment of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance has become an obstacle to the further development of immunotherapy in clinical applications and experimental studies. In the current review, the acquired resistance to immunotherapy was examined. The mechanisms of acquired resistance were based on three aspects as follows: The change of the tumor functions, the upregulated expression of inhibitory immune checkpoint proteins, and the effects of the tumor microenvironment. The combined use of immunotherapy and other therapies is performed to delay acquired resistance. A comprehensive understanding of acquired drug resistance may provide ideas for solving this dilemma.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsHumansImmunologic FactorsImmunotherapyTumor MicroenvironmentImmune Checkpoint InhibitorsImmunologic Factorsacquired resistancecombination therapyimmune checkpoint inhibitorimmunotherapythe tumor microenvironment

Identifiers

PMID35037899
PMCPMC8833108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.